Preimplantation genetic screening: back to the future
Preimplantation genetic screening: back to the future
复制标题
DOI：
10.1093/humrep/deu163
复制
发表时间：
2014-09-01
影响因子：
6.1
通讯作者：
Repping, Sjoerd
中科院分区：
文献类型：
--
作者：
Mastenbroek, Sebastiaan;Repping, Sjoerd
事后看来，所有人都同意，在常规临床实践中迅速采用胚胎植入前遗传学筛查（PGS），使用卵裂期活检和荧光原位杂交（FISH），而没有适当的（成本）效益评估，基本上导致夫妇为效果较差的治疗支付更多的钱。现在，将近20年过去了，我们正处于PGS新时代的边缘。但是，事情真的发生了变化，还是我们只是回到了未来？
All agree that in hindsight the rapid adoption of preimplantation genetic screening (PGS) using cleavage stage biopsy and fluorescence in situ hybridization (FISH) in routine clinical practice without proper evaluation of (cost-)effectiveness basically resulted in couples paying more money for a less effective treatment. Now, almost 20 years later, we are on the verge of a new era of PGS. But have things really changed or are we simply going back to the future?